Cargando…

Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate

BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) occur in various types of cancer and induce metabolic alterations resulting from the neomorphic activity that causes production of D-2-hydroxyglutarate (D-2-HG) at the expense of α-ketoglutarate (α-KG) and NADPH. To overcome metabolic stress...

Descripción completa

Detalles Bibliográficos
Autores principales: Peeters, Tom H., Lenting, Krissie, Breukels, Vincent, van Lith, Sanne A. M., van den Heuvel, Corina N. A. M., Molenaar, Remco, van Rooij, Arno, Wevers, Ron, Span, Paul N., Heerschap, Arend, Leenders, William P. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526618/
https://www.ncbi.nlm.nih.gov/pubmed/31139406
http://dx.doi.org/10.1186/s40170-019-0198-7
Descripción
Sumario:BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) occur in various types of cancer and induce metabolic alterations resulting from the neomorphic activity that causes production of D-2-hydroxyglutarate (D-2-HG) at the expense of α-ketoglutarate (α-KG) and NADPH. To overcome metabolic stress induced by these alterations, IDH-mutated (IDH(mut)) cancers utilize rescue mechanisms comprising pathways in which glutaminase and glutamate dehydrogenase (GLUD) are involved. We hypothesized that inhibition of glutamate processing with the pleiotropic GLUD-inhibitor epigallocatechin-3-gallate (EGCG) would not only hamper D-2-HG production, but also decrease NAD(P)H and α-KG synthesis in IDH(mut) cancers, resulting in increased metabolic stress and increased sensitivity to radiotherapy. METHODS: We performed (13)C-tracing studies to show that HCT116 colorectal cancer cells with an IDH1(R132H) knock-in allele depend more on glutaminolysis than on glycolysis for the production of D-2-HG. We treated HCT116 cells, HCT116-IDH1(R132H) cells, and HT1080 cells (carrying an IDH1(R132C) mutation) with EGCG and evaluated D-2-HG production, cell proliferation rates, and sensitivity to radiotherapy. RESULTS: Significant amounts of (13)C from glutamate accumulate in D-2-HG in HCT116-IDH1(wt/R132H) but not in HCT116-IDH1(wt/wt). Preventing glutamate processing in HCT116-IDH1(wt/R132H) cells with EGCG resulted in reduction of D-2-HG production. In addition, EGCG treatment decreased proliferation rates of IDH1(mut) cells and at high doses sensitized cancer cells to ionizing radiation. Effects of EGCG in IDH-mutated cell lines were diminished by treatment with the IDH1(mut) inhibitor AGI-5198. CONCLUSIONS: This work shows that glutamate can be directly processed into D-2-HG and that reduction of glutamatolysis may be an effective and promising new treatment option for IDH(mut) cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40170-019-0198-7) contains supplementary material, which is available to authorized users.